| Dr Jana Lynn Kaplan-fastow, MD | |
|
5009 Honeygo Center Dr, 210, Perry Hall, MD 21128-9828 | |
| (443) 725-2140 | |
| (410) 248-0519 |
| Full Name | Dr Jana Lynn Kaplan-fastow |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 29 Years |
| Location | 5009 Honeygo Center Dr, Perry Hall, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124009717 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | D0054793 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Luminis Health Medical Group, Llc | 2860447315 | 431 |
News Archive
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Recent research at the European Molecular Biology Laboratory (EMBL) reveals new insights into how cells achieve equality between the sexes.
Neurological disorders such as Parkinson's disease and epilepsy have had some treatment success with deep brain stimulation, but those require surgical device implantation.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.
Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett's Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.
› Verified 7 days ago
| Entity Name | Luminis Health Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073580205 PECOS PAC ID: 2860447315 Enrollment ID: O20050317000146 |
News Archive
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Recent research at the European Molecular Biology Laboratory (EMBL) reveals new insights into how cells achieve equality between the sexes.
Neurological disorders such as Parkinson's disease and epilepsy have had some treatment success with deep brain stimulation, but those require surgical device implantation.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.
Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett's Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jana Lynn Kaplan-fastow, MD 2016 Jolly Rd, Baltimore, MD 21209-1014 Ph: (410) 653-7807 | Dr Jana Lynn Kaplan-fastow, MD 5009 Honeygo Center Dr, 210, Perry Hall, MD 21128-9828 Ph: (443) 725-2140 |
News Archive
Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.
Recent research at the European Molecular Biology Laboratory (EMBL) reveals new insights into how cells achieve equality between the sexes.
Neurological disorders such as Parkinson's disease and epilepsy have had some treatment success with deep brain stimulation, but those require surgical device implantation.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young Entrepreneur Of The Year® 2013 Award in the Life Sciences category in New Jersey. Dr. Nader was presented with the award at a special gala event on June 13 at the Hyatt Regency New Brunswick, New Jersey.
Guided Therapeutics, Inc., developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it has begun human testing of its light-based detection technology for Barrett's Esophagus, a precursor for esophageal cancer. The technology is being jointly developed with Konica Minolta Opto of Japan.
› Verified 7 days ago